C3 Jian begins Phase II study of anti-cavity drug C16G2

C3 Jian has initiated the first Phase II clinical study for its C16G2, which selectively targets a cavity-causing organism Streptococcus mutans, under its US Food and Drug Administration investigational new drug (IND) application.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news